NYSE:CANO • US13781Y2028
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CANO HEALTH INC (CANO).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2023-11-17 | UBS | Downgrade | Neutral -> Sell |
| 2023-08-14 | Credit Suisse | Maintains | Neutral -> Neutral |
| 2023-08-11 | Citigroup | Downgrade | Buy -> Neutral |
| 2023-08-11 | Jefferies | Downgrade | Buy -> Hold |
| 2023-05-16 | Piper Sandler | Maintains | Underweight -> Underweight |
| 2023-05-12 | Credit Suisse | Reiterate | Neutral -> Neutral |
| 2023-01-06 | UBS | Downgrade | Buy -> Neutral |
| 2023-01-05 | Wolfe Research | Downgrade | Outperform -> Peer Perform |
| 2022-12-13 | B of A Securities | Reiterate | Underperform |
| 2022-11-16 | Citigroup | Maintains | Buy |
| 2022-11-10 | Cowen & Co. | Downgrade | Outperform -> Market Perform |
| 2022-11-10 | Raymond James | Downgrade | Outperform -> Market Perform |
| 2022-10-27 | Credit Suisse | Downgrade | Outperform -> Neutral |
| 2022-09-07 | Truist Securities | Initiate | Hold |
| 2022-06-24 | Raymond James | Initiate | Outperform |
| 2022-06-15 | B of A Securities | Downgrade | Buy -> Neutral |
| 2022-05-11 | Credit Suisse | Maintains | Outperform |
| 2022-05-11 | Piper Sandler | Maintains | Underweight |
| 2022-05-10 | Citigroup | Maintains | Buy |
| 2022-05-03 | B of A Securities | Initiate | Buy |
| 2022-04-20 | UBS | Initiate | Buy |
| 2021-10-20 | Jefferies | Initiate | Buy |
| 2021-10-19 | Piper Sandler | Initiate | Neutral |
| 2021-10-01 | Wolfe Research | Initiate | Outperform |
| 2021-09-21 | Citigroup | Initiate | Buy |
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 831.6M 130.11% | 1.609B 93.53% | 2.739B 70.18% | 3.2B 16.84% | 2.847B -11.03% | 2.959B 3.93% | 2.996B 1.25% | 3.06B 2.14% | 3.118B 1.90% | 3.175B 1.83% | 3.23B 1.73% | |
| EBITDA YoY % growth | 18.3M 735.42% | -85.76M -568.63% | -18.16M 78.82% | -251.083M -1,282.61% | -10.2M 95.94% | 90.772M 989.92% | 175.44M 93.28% | 236.64M 34.88% | 257.04M 8.62% | 278.46M 8.33% | 300.9M 8.06% | |
| EBIT YoY % growth | -200K 97.94% | -135.2M -67,500.00% | -108.8M 19.53% | -465.12M -327.50% | -53.683M 88.46% | 18.737M 134.90% | 108.12M 477.04% | 171.36M 58.49% | 189.72M 10.71% | 209.1M 10.22% | 228.48M 9.27% | |
| Operating Margin | -0.02% | -8.40% | -3.97% | -14.54% | -1.89% | 0.63% | 3.61% | 5.60% | 6.08% | 6.59% | 7.07% | |
| EPS YoY % growth | N/A | N/A | 12.90 220.45% | -165.61 -1,383.78% | -38.06 77.02% | -17.77 53.32% | N/A | N/A | N/A | N/A | N/A |
All data in USD
| Q4 / 23 | Q1 / 24 | Q2 / 24 | Q3 / 24 | Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -18.30 -146.92% | -13.33 -11.10% | -8.48 83.37% | -11.21 87.79% | -6.28 65.66% | -6.07 54.48% | -6.25 26.28% | -4.41 60.71% | -5.11 18.67% |
| Revenue Q2Q % growth | 735.36M 8.08% | 755.15M -12.89% | 706.31M -7.88% | 726.1M -7.87% | 707.6M -3.78% | 800.42M 5.99% | 720.76M 2.05% | 767.47M 5.70% | 697.69M -1.40% |
| EBITDA Q2Q % growth | -39.44M -177.27% | -6.712M 45.35% | -7.752M 95.94% | 10.96M 134.59% | 14.239M 136.10% | 19.237M 386.62% | 15.157M 295.52% | 25.102M 129.03% | 18.972M 33.24% |
| EBIT Q2Q % growth | -57.35M -44.82% | -24.449M 38.10% | -3.29M 98.66% | -20.155M 82.15% | -5.681M 90.09% | -775.2K 96.83% | -2.856M 13.18% | 5.916M 129.35% | 1.53M 126.93% |
All data in USD
9 analysts have analysed CANO and the average price target is 4.85 USD. This implies a price increase of 110.65% is expected in the next year compared to the current price of 2.3.
CANO HEALTH INC (CANO) will report earnings on 2024-02-27, after the market close.
The consensus EPS estimate for the next earnings of CANO HEALTH INC (CANO) is -18.3 USD and the consensus revenue estimate is 735.36M USD.
The expected long term growth rate for CANO HEALTH INC (CANO) is 2.61%.